Cat. No. 5280
Chemical Name: 2-[2-[(6-Methoxy-3-methyl-1H-pyrazo
Biological ActivityPotent MTH1 inhibitor (Kd = 49 nM). Inhibits Ras-induced malignant transformation and increases α-actin promoter-driven CAT activity in Ras-transformed cells. Has no effect on Ras-induced ERK and JNK activation. Inhibits Ras-induced membrane ruffling in REF-52 fibroblasts and blocks anchorage-independent growth of Ras-transformed tumor cell lines. Also induces DNA damage in SW480 colon cancer cells.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Huber et al (2014) Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature 508 222. PMID: 24695225.
Kumar et al (1999) SCH 51344, an inhibitor of RAS/RAC-mediated cell morphology pathway. Ann.N.Y.Acad.Sci. 886 122. PMID: 10667210.
Walsh et al (1997) SCH 51344-induced reversal of RAS-transformation is accompanied by the specific inhibition of the RAS and RAC-dependent cell morphology pathway. Oncogene 15 2553. PMID: 9399643.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses SCH 51344 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: SCH 51344, supplier, SCH51344, potent, MTH1, inhibitors, inhibits, ras, transformation, anticancer, hydrolases, g, proteins, mutT, homologue, NUDT1, Tocris Bioscience, Other Hydrolase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent and selective poly (ADP ribose) glycohydrolase (PARG) inhibitor; cell permeableJZP 361
Potent and selective reversible MAGL inhibitorURB 602
Non-competitive MAGL inhibitor(S)-Crizotinib
Potent soluble epoxide hydrolase inhibitor; orally bioavailable and brain penetrantJZP 430
Potent and irreversible α/β-hydrolase domain 6 (ABHD6) inhibitor
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.